GCI Subsiduary PhytoPain Pharma Announces Submission of …

OTTAWA, ONTARIO–(Marketwired – Sept. 6, 2016) – PhytoPain Pharma Inc. (“PhytoPain Pharma
or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the
Company“) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of
Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for
the treatment of patients with Complex Regional Pain Syndrome Type 1 (CRPS1) and patients with Central PostStroke Pain
(CPSP). The decision to proceed with these Orphan Drug Designation submissions is part of PPP’s plan to move forward with
the development of a cannabis prescription drug product for the treatment of neuropathic pain associated with CRPS1 and
CPSP. If successful, the designation of delta-9-tetrahydrocannibinol and cannabidiol as an Orphan Drug will open the door
for many opportunities most notably tax credits on clinical

... read more at: http://www.stockhouse.com/news/press-releases/2016/09/06/gci-subsiduary-phytopain-pharma-announces-submission-of-orphan-drug-designation